Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis - Wikidata - wikimedia - TriplyDB

Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis

Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis

http://www.wikidata.org/entity/Q33886243

about

Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma Positron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patients Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.Histone deacetylase inhibitors: emerging mechanisms of resistance.Contrasting dynamic responses in vivo of the Bcl-xL and Bim erythropoietic survival pathways.Kinase inhibitors in the treatment of immune-mediated disease Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia Advances in paediatric cancer treatment Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma A novel class of piperidones exhibit potent, selective and pro-apoptotic anti-leukemia properties.Cancer prevention and therapy through the modulation of the tumor microenvironment.Tumor-selective cytotoxicity of a novel pentadiene analogue on human leukemia/ lymphoma cells YKT6 expression, exosome release, and survival in non-small cell lung cancer.Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.Curcuma Contra Cancer? Curcumin and Hodgkin's Lymphoma.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.An update on emerging drugs for Hodgkin lymphoma.Profile of pacritinib and its potential in the treatment of hematologic disorders.Cytokine Signaling in Tumor Progression.Simultaneous assessment of NF-κB/p65 phosphorylation and nuclear localization using imaging flow cytometry Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells.Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs.Paradoxical Role of High Mobility Group Box 1 in Glioma: A Suppressor or a Promoter?HiJAKing the epigenome in leukemia and lymphoma.PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma.Clinical and prognostic significance of high-mobility group box-1 in human gliomas.HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape.Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.Oxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2/STAT3 pathway Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models

P2860

Q24186668-7E9315A9-07DA-45FC-82AC-85F96F82EA57 Q24202622-F1C4F2A1-B635-41C8-BF5F-8B1F0A283084 Q28079232-EDFCE820-D853-49DD-A15D-1CF0554616F8 Q28389722-457F4931-ED8E-443F-9C1D-8AA61D72ECC3 Q33886267-51DAD851-F141-4230-BE14-2A09FE4A28CE Q33913937-FDBAA827-A7D8-4B69-8F97-4DC88FACE0BD Q34501206-8417442B-E9A0-4FE2-95BD-E9DB39150868 Q34648812-6CD39A60-A981-4152-BA0D-E2DB838C59D1 Q35592607-BBF851D0-2920-42A7-8E65-914F90330201 Q35750349-72BD3FA3-0CD5-4B57-9951-54169B43AB59 Q35814037-C3B945DC-362C-4BD1-A08B-81C63199AF4E Q36155080-1C13BA62-B526-4A21-A7A5-85F6BEA1D21E Q36508630-249223EF-26FC-49FB-BE86-53F3061F7719 Q36598782-8980CA98-1162-4EC8-A105-534C6CC4AE9F Q36954631-BEED6D30-FAC0-4B63-89EA-17537A8B807D Q37058267-803C727A-1B28-4132-889A-2FE6C140ED77 Q37415621-3EB4E81B-CB5D-4ECF-986E-8FD3EAB2BEF5 Q37588313-A86E3CEA-6602-4116-B3AE-F62EF40CA1E9 Q38132817-983B2446-6B96-4059-B7A7-20CFA36F8843 Q38150876-BF1892F5-C383-47D6-AEAE-3351ACEB943C Q38199088-4FA9E87F-5F28-4F2D-9FB4-7B39E308ABB8 Q38203779-02CDF87D-8B36-460C-9A78-345298C86EB0 Q38205874-412BAFD3-E27C-4933-B031-49E464F1AC51 Q38244524-EEC9BA8C-67DF-4BC2-BB16-9620154F8DE0 Q38598868-E61458A5-BFB8-4C04-B743-DC65D0EB0404 Q38888723-96850BA1-5E64-488A-855F-7826E3335264 Q38930827-CF206940-0B3B-43B5-B8F6-0384E2E46C48 Q39171993-304902BE-770A-4FF1-9860-6E76792B149F Q39223354-3ADD4197-5A67-4B10-A814-C4F85D8E91A4 Q39237403-5AB83C3D-F7C8-43EC-AA3F-93DC679A10C2 Q40853718-F751BC9B-47C1-44DE-A0B9-710143EC3860 Q41983273-44EEC60E-6196-48BE-8347-B16CC3FED062 Q42149043-3E2DD128-88F1-4CA9-988C-724125B873BB Q47140442-4A102287-D010-42B3-BD02-568D9A10E07F Q49912597-1521557D-6373-4F76-A9D2-D849AF895DD3 Q58782158-216F336D-D380-4FD0-A830-A730E5F9CFF7 Q59129787-27F15398-7019-4C60-B35D-5FEB253100A6

P2860

Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis

http://www.wikidata.org/entity/Q33886243

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Lestaurtinib inhibition of the ...... feration and induces apoptosis

@ast

Lestaurtinib inhibition of the ...... feration and induces apoptosis

@en

type

label

Lestaurtinib inhibition of the ...... feration and induces apoptosis

@ast

Lestaurtinib inhibition of the ...... feration and induces apoptosis

@en

prefLabel

Lestaurtinib inhibition of the ...... feration and induces apoptosis

@ast

Lestaurtinib inhibition of the ...... feration and induces apoptosis

@en

P1433

Q33886243-9D88789B-C773-4380-9BD8-6EEDBCC64D9F

P1476

Q33886243-ACCC424D-FEA4-4035-91D9-2A50FB6B311E

P2093

Q33886243-118A595E-8387-42DB-8534-5B1EB6AE2E9E

Q33886243-390568B7-6265-421A-BE8E-DBA883E7E4CF

Q33886243-39CDB537-A611-4559-BFA4-3DCD2CEDAFBE

Q33886243-84B05127-5989-494D-8D4C-CAFC8C0FB9B9

Q33886243-93977321-9526-4874-8DDA-7B8A7401F3B2

Q33886243-956307E8-0132-4C07-AEF6-E581B9B1B018

Q33886243-A494D1D1-BF43-4ACE-B7EC-D015AF54F788

Q33886243-B40D2F13-1DDE-4B5D-9562-DF653CB12592

Q33886243-D6F04BCF-04BC-4B50-9B6C-9B1B6034904D

P2860

Q33886243-0454CC12-6520-4344-80C1-E71236455066

Q33886243-2FAA60A0-35CB-466B-B7B8-F07B27E951F3

Q33886243-307C80E1-B9E1-494E-ADE1-9487E6B8C064

Q33886243-3122A188-9E9F-4F27-B8E5-7D2C919CC60D

Q33886243-32894CF6-389C-4316-B33A-9D8C98B00225

Q33886243-41988207-3B53-4AD1-9C82-BC47F6336242

Q33886243-4F8E4FA3-B525-4F58-B124-C5D1C12E0268

Q33886243-6A8D1724-46AA-44E4-8078-4FEC59E09B5A

Q33886243-7E87F78D-519A-4CDF-8A27-31DD0EB2F5B4

Q33886243-7F86FF1F-4148-48D0-87EC-CEE0C16CF585

P304

Q33886243-924CF80F-40F4-4411-BB5D-B589FD8E0456

P31

Q33886243-1F8D134B-7CC7-49E9-8728-140E05A5F6D2

P356

Q33886243-5C46D7CC-8352-42B1-8C96-619EB8D90BF1

P407

Q33886243-475C1226-F63A-4B3E-ADE5-C8FE32AEE427

P433

Q33886243-383D6E9E-6B94-4D17-A38C-E5C8BA4F3A1A

P478

Q33886243-EBEC2774-F61E-4FC0-BCBE-1CF51A9B098E

P50

Q33886243-0B3C11D3-3E5E-4EDD-8B2C-E6CE492157C8

Q33886243-0CAA7BB3-90AA-4A3B-8CB8-B026F38E3F9C

P577

Q33886243-0BA05156-F73D-4579-B72D-1D7A4ED9864C

P5875

Q33886243-EB3C0156-0EF4-44D1-9DE7-10266F864139

P698

Q33886243-94558ED9-029C-42A9-BA63-FBCCB3892596

P932

Q33886243-E5D84EE1-65DE-4924-B984-D493470569A0

P356

JOURNAL.PONE.0018856

P1433

P1476

Lestaurtinib inhibition of the ...... feration and induces apoptosis

@en

P2093

Anna Gaya

http://www.w3.org/2001/XMLSchema#string

Antonio Martínez

http://www.w3.org/2001/XMLSchema#string

Beatriz Bellosillo

http://www.w3.org/2001/XMLSchema#string

Bernat Gel

http://www.w3.org/2001/XMLSchema#string

Gerardo Ferrer

http://www.w3.org/2001/XMLSchema#string

Mar Garcia-Garcia

http://www.w3.org/2001/XMLSchema#string

Mariano Monzo

http://www.w3.org/2001/XMLSchema#string

Sergi Serrano

http://www.w3.org/2001/XMLSchema#string

Tania Diaz

http://www.w3.org/2001/XMLSchema#string

P2860

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.

Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

Novel small-molecule therapy of Hodgkin lymphoma.

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.

Risk, cure and complications in advanced hodgkin disease.

P304

e18856

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0018856

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51089287

http://www.w3.org/2001/XMLSchema#string

P698

21533094

http://www.w3.org/2001/XMLSchema#string

P932

3080386

http://www.w3.org/2001/XMLSchema#string